

Sensitivity Analyses — Inclusion of the Turquoise-II Study Naive Genotype 1 With Cirrhosis

TABLE 174: NAIVE GENOTYPE 1 WITH CIRRHOSIS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 + SOF12	PR48	2.22 (1.08 to 2.94)	48.99 (3.16 to 63.54)
T12 PR24-48 RGT q8		1.44 (0.74 to 2.21)	17.23 (−10.45 to 42.95)
T12 PR24-48 RGT q12		1.54 (0.66 to 2.38)	21.12 (−13.48 to 48.53)
SOF12 + PR12		2.09 (1.28 to 2.78)	43.29 (11.47 to 58.91)
SIM12 PR24-48 RGT		1.69 (1.08 to 2.40)	27.11 (3.34 to 47.28)
B24 PR28-48 RGT		0.66 (0.16 to 1.63)	−13.08 (−35.34 to 23.67)
SOF12 + SIM12 + RBV12		2.25 (0.41 to 3.00)	50.89 (−22.88 to 65.24)
SOF24 + RBV24		1.76 (0.66 to 2.59)	30.10 (−13.25 to 55.01)
DCV24 + ASU24		2.28 (1.69 to 2.95)	50.22 (29.77 to 62.37)
SOF12 + LDV12		2.44 (1.96 to 3.09)	56.51 (42.80 to 66.01)
SOF12 + LDV12 + RBV12		2.44 (1.96 to 3.09)	56.56 (43.48 to 65.87)
SOF24 + LDV24 + RBV24		2.45 (1.97 to 3.11)	56.93 (43.84 to 66.44)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.42 (1.94 to 3.06)	55.49 (42.85 to 64.82)
T12 PR24-48 RGT q8	SIM12 + SOF12	0.67 (0.36 to 1.24)	−28.78 (−57.23 to 10.88)
T12 PR24-48 RGT q12		0.72 (0.32 to 1.32)	−24.72 (−60.18 to 15.99)
SOF12 + PR12		0.94 (0.65 to 1.69)	−5.05 (−29.71 to 31.70)
SIM12 PR24-48 RGT		0.77 (0.49 to 1.61)	−20.19 (−47.71 to 26.43)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
B24 PR28-48 RGT		0.31 (0.07 to 0.89)	-59.15 (-86.56 to -6.43)
SOF12 + SIM12 + RBV12		1.01 (0.22 to 1.57)	1.04 (-58.70 to 31.30)
SOF24 + RBV24		0.81 (0.32 to 1.54)	-16.87 (-59.14 to 25.23)
DCV24 + ASU24		1.01 (0.77 to 2.11)	0.65 (-22.00 to 48.31)
SOF12 + LDV12		1.07 (0.91 to 2.25)	6.61 (-8.60 to 53.08)
SOF12 + LDV12 + RBV12		1.07 (0.91 to 2.26)	6.43 (-8.47 to 53.01)
SOF24 + LDV24 + RBV24		1.08 (0.91 to 2.27)	7.19 (-8.10 to 53.26)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.06 (0.91 to 2.23)	5.63 (-8.91 to 52.15)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.06 (0.64 to 1.52)	3.42 (-18.50 to 22.87)
SOF12 + PR12		1.42 (1.08 to 2.30)	23.84 (5.10 to 44.40)
SIM12 PR24-48 RGT		1.18 (0.66 to 2.47)	9.95 (-25.21 to 44.74)
B24 PR28-48 RGT		0.46 (0.11 to 1.42)	-29.48 (-64.33 to 15.89)
SOF12 + SIM12 + RBV12		1.49 (0.31 to 2.98)	29.33 (-37.44 to 61.92)
SOF24 + RBV24		1.19 (0.60 to 1.95)	11.04 (-20.30 to 37.40)
DCV24 + ASU24		1.57 (1.01 to 3.15)	32.45 (0.89 to 62.70)
SOF12 + LDV12		1.69 (1.15 to 3.37)	38.82 (11.78 to 67.90)
SOF12 + LDV12 + RBV12		1.69 (1.15 to 3.36)	38.93 (11.74 to 67.66)
SOF24 + LDV24 + RBV24		1.70 (1.15 to 3.35)	39.39 (12.21 to 67.49)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.67 (1.14 to 3.33)	38.02 (11.46 to 66.83)
SOF12 + PR12	T12 PR24-48 RGT q12	1.33 (0.95 to 2.68)	19.94 (-3.43 to 48.53)
SIM12 PR24-48 RGT		1.10 (0.62 to 2.71)	5.89 (-30.00 to 47.20)
B24 PR28-48 RGT		0.44 (0.10 to 1.43)	-32.68 (-69.24 to 14.99)
SOF12 + SIM12 + RBV12		1.40 (0.29 to 3.25)	25.53 (-41.27 to 64.49)
SOF24 + RBV24		1.12 (0.71 to 1.77)	7.29 (-14.57 to 29.48)
DCV24 + ASU24		1.47 (0.95 to 3.47)	28.34 (-4.18 to 64.84)
SOF12 + LDV12		1.58 (1.08 to 3.72)	34.99 (6.41 to 70.42)
SOF12 + LDV12 + RBV12		1.58 (1.08 to 3.71)	34.98 (6.44 to 70.18)
SOF24 + LDV24 + RBV24		1.59 (1.08 to 3.71)	35.55 (7.05 to 70.33)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.56 (1.07 to 3.66)	33.84 (5.76 to 69.04)
SIM12 PR24-48 RGT	SOF12 + PR12	0.82 (0.52 to 1.41)	-15.20 (-43.43 to 21.59)
B24 PR28-48 RGT		0.32 (0.08 to 0.87)	-54.62 (-82.04 to -8.07)
SOF12 + SIM12 + RBV12		1.08 (0.21 to 1.62)	6.51 (-62.09 to 35.08)
SOF24 + RBV24		0.85 (0.37 to 1.26)	-12.07 (-48.26 to 15.90)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24		1.08 (0.82 to 1.79)	6.51 (-16.15 to 40.48)
SOF12 + LDV12		1.15 (0.95 to 1.91)	12.55 (-4.97 to 45.73)
SOF12 + LDV12 + RBV12		1.15 (0.95 to 1.90)	12.64 (-4.68 to 45.31)
SOF24 + LDV24 + RBV24		1.16 (0.95 to 1.90)	13.31 (-4.24 to 45.52)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.14 (0.95 to 1.88)	11.74 (-4.14 to 44.33)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	0.39 (0.09 to 1.08)	-39.57 (-69.62 to 4.06)
SOF12 + SIM12 + RBV12		1.31 (0.24 to 2.06)	21.23 (-51.74 to 49.44)
SOF24 + RBV24		1.04 (0.38 to 1.78)	2.66 (-45.02 to 37.83)
DCV24 + ASU24		1.34 (0.94 to 2.08)	22.69 (-4.48 to 48.44)
SOF12 + LDV12		1.44 (1.09 to 2.20)	29.19 (7.64 to 52.79)
SOF12 + LDV12 + RBV12		1.44 (1.09 to 2.20)	29.16 (7.20 to 52.73)
SOF24 + LDV24 + RBV24		1.44 (1.10 to 2.20)	29.47 (7.91 to 53.01)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.42 (1.09 to 2.17)	28.10 (7.34 to 51.42)
SOF12 + SIM12 + RBV12	B24 PR28-48 RGT	3.19 (0.51 to 13.44)	60.22 (-18.66 to 88.99)
SOF24 + RBV24		2.58 (0.74 to 10.46)	41.22 (-12.10 to 76.76)
DCV24 + ASU24		3.43 (1.38 to 14.04)	62.40 (22.54 to 85.85)
SOF12 + LDV12		3.69 (1.51 to 15.07)	69.24 (31.18 to 90.33)
SOF12 + LDV12 + RBV12		3.68 (1.53 to 15.09)	69.04 (32.39 to 90.38)
SOF24 + LDV24 + RBV24		3.71 (1.53 to 15.13)	69.73 (32.37 to 90.58)
PAR/RIT12 + OMB12 + DAS12 + RBV12		3.66 (1.49 to 14.97)	68.41 (30.39 to 89.49)
SOF24 + RBV24	SOF12 + SIM12 + RBV12	0.81 (0.32 to 3.98)	-17.40 (-61.76 to 52.99)
DCV24 + ASU24		0.99 (0.77 to 5.48)	-1.08 (-22.14 to 73.62)
SOF12 + LDV12		1.05 (0.89 to 5.86)	4.67 (-11.21 to 78.43)
SOF12 + LDV12 + RBV12		1.05 (0.91 to 5.91)	4.32 (-8.88 to 78.88)
SOF24 + LDV24 + RBV24		1.06 (0.90 to 5.94)	5.74 (-9.71 to 78.89)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.04 (0.89 to 5.90)	3.84 (-10.90 to 78.47)
DCV24 + ASU24	SOF24 + RBV24	1.28 (0.88 to 3.50)	19.49 (-10.48 to 64.94)
SOF12 + LDV12		1.37 (1.00 to 3.79)	25.91 (-0.17 to 71.20)
SOF12 + LDV12 + RBV12		1.38 (0.99 to 3.76)	26.00 (-1.11 to 70.88)
SOF24 + LDV24 + RBV24		1.38 (1.00 to 3.74)	26.72 (0.23 to 70.13)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.36 (0.99 to 3.65)	25.06 (-0.49 to 68.39)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12	DCV24 + ASU24	1.07 (0.91 to 1.36)	6.16 (−8.56 to 25.37)
SOF12 + LDV12 + RBV12		1.07 (0.92 to 1.35)	6.10 (−7.38 to 24.90)
SOF24 + LDV24 + RBV24		1.07 (0.92 to 1.37)	6.46 (−7.89 to 26.15)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.06 (0.91 to 1.36)	4.95 (−8.49 to 25.11)
SOF12 + LDV12 + RBV12	SOF12 + LDV12	1.00 (0.89 to 1.12)	0.01 (−10.24 to 9.81)
SOF24 + LDV24 + RBV24		1.00 (0.89 to 1.14)	0.42 (−10.75 to 12.10)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.88 to 1.14)	−1.20 (−12.06 to 12.13)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.00 (0.89 to 1.13)	0.41 (−10.85 to 11.39)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.87 to 1.14)	−1.17 (−12.32 to 12.08)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF24 + LDV24 + RBV24	0.98 (0.87 to 1.12)	−1.50 (−12.72 to 10.46)
Random effect model	Residual deviance	28.88 vs. 32 data points	
	Deviance information criteria	152.357	
Fixed effect model	Residual deviance	28.46 vs. 32 data points	
	Deviance information criteria	151.451	

ASU = asunaprevir; B = boceprevir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.